ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Jackson Creek Investment Advisors LLC

Jackson Creek Investment Advisors LLC reduced its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 3.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,603 shares of the specialty pharmaceutical company’s stock after selling 580 shares during the period. Jackson Creek Investment Advisors LLC owned 0.09% of ANI Pharmaceuticals worth $1,028,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Thrivent Financial for Lutherans increased its holdings in shares of ANI Pharmaceuticals by 2.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after buying an additional 299 shares during the last quarter. Exchange Traded Concepts LLC grew its position in ANI Pharmaceuticals by 2.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock worth $684,000 after acquiring an additional 310 shares during the period. New York State Teachers Retirement System grew its position in ANI Pharmaceuticals by 1.7% in the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock worth $1,439,000 after acquiring an additional 394 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in ANI Pharmaceuticals by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock worth $246,000 after acquiring an additional 412 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its position in ANI Pharmaceuticals by 5.2% in the third quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company’s stock valued at $564,000 after purchasing an additional 464 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at ANI Pharmaceuticals

In related news, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at $8,617,769.72. The trade was a 4.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the completion of the sale, the senior vice president now directly owns 68,624 shares in the company, valued at $4,131,164.80. This represents a 1.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,300 shares of company stock valued at $584,009. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $60.62 on Friday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.81. The firm has a market cap of $1.27 billion, a PE ratio of -110.22 and a beta of 0.63. The company’s 50 day moving average is $57.64 and its two-hundred day moving average is $58.13.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Guggenheim increased their price target on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, March 3rd. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target on the stock. StockNews.com lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. Finally, Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.00.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.